comparemela.com
  1. Home
  2. Live Updates
  3. Flavius Martin - Breaking News

Latest Breaking News On - Flavius martin - Page 11 : comparemela.com

Gilead Sciences, Inc (GILD) Management presents at Bernstein 38th Annual Strategic Decisions Conference - Transcript

Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Bernstein 38th Annual Strategic Decisions Conference June 1, 2022 16:30 ET CorporateParticipants Andrew Dickinson - Chief Financial Officer.

United statesPaul stoffelsAndrew dickinsonFlavius martinEli lillyRonny galLinda higginsDepartment of justiceOur head of researchGilead sciences incNovo nordiskGilead sciencesAnnual strategic decisions conference juneDano dayCell therapyFederal trade commission

Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation

Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics today announced a collaboration designed to advance a number of Dragonfly's novel natural killer (NK) cell engager-based immunotherapies for oncology and inflammation indications. NK cell engagers represent a novel mechanism with the potential .

Foster cityUnited statesFlavius martinExchange commissionGilead sciencesTherapeutics incResearch at gileadGilead public affairsGilead sciences incLicense exclusive worldwide rightsInvestigational candidateHave optionsLicense several additionalDragonfly therapeuticsDragonfly tri specificInvestigational new drug

Gilead signs $300m deal with Dragonfly to advance immunotherapies

Gilead signs $300m deal with Dragonfly to advance immunotherapies
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Flavius martinGilead sciencesDragonfly therapeuticsInvestigational new drug

Gilead snaps up Dragonfly s NK program, has options for more

The $300 million Dragonfly deal seeks to expand Gilead's oncology portfolio, which saw sales surge 60% last quarter to $420 million.

United statesFlavius martinGilead sciencesDrug administrationDragonfly therapeuticsInvestigational new drug

Gilead Sciences (GILD) Q1 2021 Earnings Call Transcript

GILD earnings call for the period ending March 31, 2021.

United statesRobyn karnauskasHartaj singhMerdad parseyTerence flynn goldman sachsAndrew dickinsonLouise pearson redburnMerck keytrudaJohanna mercierTerence flynnMichael yeePhil nadeau cowenBrian abrahamsAtripla loesGeoff meachamJohn martin

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.